

POUŽITÁ LITERATURA

1. Dolder R, Skinner FS, editors. *Ophthalmica. Pharmakologie, Biopharmazie und Galenik der Augenarzneimittel*. 3. Aufl., Stuttgart: Wissenschaftl. Verlagsgesellschaft; 1983.
2. Addo RT, editor. *Ocular drug delivery: Advances, challenges and applications*. Cham: Springer Int. Publ.; 2016.
3. Kaur IP, Kanwar M. Ocular preparations: The formulation approach. *Drug Dev Ind Pharm*. 2002;28(5):473–93.
4. Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, et al. Principles of pharmacology in the eye. *Br J Pharmacol*. 2017;174(23):4205–23.
5. Synek S, Skorkovská Š. *Fyziologie oka a vidění*. 2nd ed. Praha: Grada Publ.; 2014.
6. Freddo TF, Chaum E. *Anatomy of the Eye and Orbit: The Clinical Essentials*. Philadelphia: Wolters Kluwer Health; 2018.
7. Dartt DA. Regulation of tear secretion. *Adv Exp Med Biol*. 1994;350:1–9.
8. Tiffany JM. The normal tear film. In: Geerling G, Brewitt H, editors. *Surgery for the Dry Eye*. Karger: Dev Ophthalmol Basel; 2008.
9. Bron AJ, Tiffany JM, Gouveia SM, Yokoi N, Voon LW. Functional aspects of the tear lipid layer. *Exp Eye Res*. 2004;78(3):347–60.
10. Robinson JR. Ocular anatomy and physiology. In: Mitra AK, editor. *Ophthalmic drug delivery systems*. New York: Marcel Dekker; 1993.
11. Tsai PS, Evans JE, Green KM, Sullivan RM, Schaumberg DA, Richards SM et al. Proteomic analysis of human meibomian gland secretions. *Br J Ophthalmol*. 2006;90:372–77.
12. Spurr-Michaud S, Argüeso P, Gipson I. Assay of mucins in human tear fluid. *Exp Eye Res*. 2007;84(5):939–50.
13. Winter KN, Anderson DM, Braun RJ. A model for wetting and evaporation of a post-blink precorneal tear film. *Mathematical Medicine and Biology. A Journal of the IMA*. 2010;27(3):211–25.
14. Tsubota K. Tear dynamics and dry eye. *Prog Ret Eye Res*. 1998;17(4):565–96.
15. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular delivery. *Pharm Res*. 2009;26(5):1197–216.
16. Lee YH, Kompella UB, Lee VHL. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit. *Exp Eye Res*. 1993;57(3):341–9.
17. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. *Drug Dev Ind Pharm*. 2013;39(11):1599–617.
18. Sasaki H, Yamamura K, Nishida K, Nakamura J, Ichikawa M. Delivery of drugs to the eye by topical application. *Prog Retinal Eye Res*. 1996;15(2):583–620.
19. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. *Adv Drug Del Rev*. 2006;58(11):1131–5.
20. Dey S, Patel J, Anand BS, Jain-Vakkalagadda B, Kaliki P, Pal D, et al. Molecular evidence and functional expression of p-glycoprotein in human and rabbit cornea and corneal epithelial cell lines. *Invest Ophthalmol Vis Sci*. 2003;44(7):2909–18.
21. Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. *J Glaucoma*. 2008;17(2):147–56.

22. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood–retina barrier: Emerging role of transporters in ocular pharmacokinetics. *Adv Drug Del Rev.* 2006;58(11):1136–63.
23. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. *J Pharm Sci.* 1998;87(12):1479–88.
24. Missel PJ, Lang JC, Rodeheaver DP, Jani R, Chowhan MA, Chastain J, et al. Design and evaluation of ophthalmic pharmaceutical products. In: Florence AT, Siepmann J, editors. *Modern Pharmaceutics. Vol. 2. Applications and Advances. 5th Ed.* New York: Informa Healthcare; 2009.
25. Lederer CM Jr., Harold RE. Drop size of commercial glaucoma medications. *Am J Ophthalmol.* 1986;101(6):691–4.
26. Módis L, Langenbucher A, Seitz B. Corneal thickness measurements with contact and noncontact specular microscopic and ultrasonic pachymetry. *Am J Ophthalmol.* 2001;132(4):517–21.
27. Lang JC. Ocular drug delivery conventional ocular formulations. *Adv Drug Del Rev.* 1995;16:39–43.
28. Grass GM, Robinson JR. Mechanisms of corneal drug penetration I: In vivo and in vitro kinetics. *J Pharm Sci.* 1988;77(1):3–14.
29. Fu XC, Liang WQ. Prediction of corneal permeability using polar molecular surface areas. *Pharmazie.* 2001;56(8):667.
30. Fu, XC, Liang WQ. A simple model for the prediction of corneal permeability. *Int J Pharm.* 2002;232(1–2):193–7.
31. Rae JL. Ion channels in ocular epithelia. *Invest Ophthalmol Vis Sci.* 1993;34:2608–12.
32. Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. *Eur J Pharm Biopharm.* 2005;60(2):207–25.
33. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. *J Pharm Sci.* 1987;76(8):583–6.
34. Hosoya K, Lee VHL, Kim KJ. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. *Eur J Pharm Biopharm.* 2005;60(2):227–40.
35. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. *Prog Ret Eye Res.* 2002;21(2):145–51.
36. Loftsson T, Sigurdsson HH, Konrádssdóttir F, Gísladóttir S, Jansook P, Stefánsson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. *Pharmazie.* 2008;63(3):171–9.
37. Okáčová L, Vetchý D, Franc A, Rabišková M. Zvýšení biodostupnosti těžce rozpustných léčivých látek technologickými postupy usnadňujícími jejich rozpouštění. *Chem Listy.* 2011;105:34–40.
38. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. *Ther Deliv.* 2010;1(3):435–56.
39. Greaves JL, Olejnik O, Wilson CG. Polymers and the precorneal tear film. *S.T.P. Pharm Sci.* 1992;63:13–33.
40. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. *Adv Drug Deliv Rev.* 2005;57(11):1595–1639.
41. Hartmann V, Keipert S. Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use. *Pharmazie.* 2000;55(6):440–3.
42. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. *J Control Release.* 2007;122(2):119–34.
43. Bhardway TR, Kanwar M, Lal R, Gupta A. Natural gums and modified natural gums as sustained-release carriers. *Drug Dev Ind Pharm.* 2000;26(10):1025–38.
44. Rinaudo M. Relation between the molecular structure of some polysaccharides and original properties in sol and gel states. *Food Hydrocoll.* 2001;15(4–6):433–40.

45. Saettone MF, Giannaccini B, Monti D. Ophthalmic emulsions and suspensions. *J Toxicol Cut & Ocular Toxicol*. 2001;20(2–3):183–201.
46. Suhonen P, Järvinen T, Rytönen P, Peura P, Urtti A. Improved corneal pilocarpine permeability with O,O'-(1,4-xylylene)bis-pilocarpic acid ester double prodrugs. *Pharm Res*. 1991;8:1539–42.
47. Sznitowska M, Zurowska-Pryczkowska K, Janicki S, Järvinen T. Miotic effect and irritation potential of pilocarpine prodrug incorporated into a submicron emulsion vehicle. *Int J Pharm*. 1999;184(1):115–20.
48. Tirucherai GS, Dias C, Mitra AK. Corneal permeation of ganciclovir: Mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. *J Ocul Pharmacol Ther*. 2002;18(6):535–48.
49. Loftsson T, Vogensen SB, Brewster ME, Konradottir F. Effects of cyclodextrins on drug delivery through biological membranes. *J Pharm Sci*. 2007;96(10):2532–46.
50. Loftsson T, Stefánsson E. Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. *Acta Ophthalmol Scand*. 2002;80:144–50.
51. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. *J Control Rel*. 2009;136(1):2–13.
52. Barar J, Aghanejad A, Fathi M, Omid Y. Advanced drug delivery and targeting technologies for the ocular diseases. *Bioimpacts*. 2016;6(1):49–67.
53. Lallemand F, Daul P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. *Journal of Drug Delivery*. 2012.
54. Neves J, Sarmiento B. *Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies*. New York: Springer; 2014.
55. Pinheiro R, Panfil C, Schrage N, Dutescu RM. Comparison of the lubricant eyedrops Optive(R), Vismed Multi(R), and Cationorm(R) on the corneal healing process in an ex vivo model. *Eur J Ophthalmol*. 2015;25:379–84.
56. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, et al. Enhancement of ocular drug penetration. *Crit Rev Ther Drug Car Syst*. 1999;16(1):85–146.
57. Sasaki H, Nagano T, Yamamura K, Nishida K, Nakamura J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. *J Pharm Pharmacol*. 1995;47(9):703–7.
58. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. *Drug Dev Ind Pharm*. 2002;28(4):353–69.
59. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, et al. Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four beta-blockers, and in vitro/in vivo toxic activity. *Int J Pharm*. 1996;142(1):103–13.
60. Rojanasakul Y, Liaw J, Robinson JR. Mechanisms of action of some penetration enhancers in the cornea - laser scanning confocal microscopic and electrophysiology studies. *Int J Pharm*. 1990;66(1–3):131–42.
61. Mitra AK, editor. *Treatise on Ocular Drug Delivery*. Bentham Science Publ. 2013.
62. Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF. Effect of iontophoresis on transcorneal permeation 'in vitro' of two β -blocking agents, and on corneal hydration. *Int J Pharm*. 2002;250(2):423–9.
63. Chader GJ, Taylor A. Preface: The Aging Eye: Normal changes, age-related diseases, and sight-saving approaches. *Invest Ophthalmol Vis Sci*. 2013;54(14):1–4.
64. Madni A, Rahem MA, Tahira N, Sarfraz M, Jabara A, Rehmana M, et al. Non-invasive strategies for targeting the posterior segment of eye. *Int J Pharm*. 2017;530:326–45.
65. Thrimawithana T, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. *Drug Discovery Today*. 2011;16(5–6):270–7.
66. Lee J, Pelis RM. Drug Transport by the Blood–Aqueous Humor Barrier of the Eye. *Drug Metab Dispos*. 2016;44(10):1675–81.
67. Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. *J Control Rel*. 2014;193:100–12.

68. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. *Pharm Res.* 2003;20(4):576–83.
69. Choonara YE, Pillay V, Danckwerts MP, Carmichael TR, Du Toit LC. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. *J Pharm Sci.* 2010;99(5):2219–39.
70. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. *Expert Opin Drug Deliv.* 2007;4(4):371–88.
71. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. *Surv Ophthalmol.* 1993;37(6):435–56.
72. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. *Am J Ophthalmol.* 1986;102(2):606–11.
73. Fraunfelder FT, Meyer SM. Systemic side effects from ophthalmic timolol and their prevention. *J Ocular Pharmacol.* 1987;3(2):177–184.
74. Patton T. Pharmacokinetic evidence for improved ophthalmic drug delivery by reducing of instilled volume. *J Pharm Sci.* 1977;66(7):1058–9.
75. Chrai SS, Patton TF, Mehta A, Robinson JR. Lacrimal and instilled fluid dynamics in rabbit eyes. *J Pharm Sci.* 1973;62(7):1112–21.
76. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size initial dosing frequency problems of topically applied ophthalmic drugs. *J Pharm Sci.* 1974;63(3):333–8.
77. Ludwig A, van Ooteghem M. The influence of the drop size on the elimination of an ophthalmic solution from the precorneal area of human eyes. *Drug Dev Ind Pharm.* 1986;12(11–13):2231–42.
78. German EJ, Hurst MA, Wood D. Reliability of drop size from multi-dose eye drop bottle: is it cause for concern? *Eye.* 1999;13(Pt 1):93–100.
79. Šklubalová Z, Zatloukal Z. Systematic study of factors affecting the eye drop size and dosing variability. *Pharmazie.* 2005;60(12):917–21.
80. van Santvliet L, Ludwig A. The influence of penetration enhancers on the volume instilled of eye drops. *Eur J Pharm Biopharm.* 1998;45(2):189–98.
81. Šklubalová Z, Zatloukal Z. Classification of plastic eye dropper tips using Harkins and Brown's factor. *Pharmazie.* 2007;62(10):750–5.
82. Jho C, Burke R. Drop weight technique for the measurement of dynamic surface-tension. *J Colloid Interface Sci.* 1983;95:61–71.
83. Jho C, Carreras M. The effect of viscosity on the drop weight technique for the measurement of dynamic surface-tension. *J. Colloid Interface Sci.* 1984;99:543–8.
84. Cheboyina S, O'Haver J, Wyandt CM. A mathematical model to predict the size of the pellets formed in freeze pelletization techniques: Parameters affecting pellet size. *J Pharm Sci.* 2006;95(1):167–80.
85. van Santvliet L, Ludwig A. Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle. *Eur J Pharm Sci.* 1999;7(4):339–45.
86. van Santvliet L, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles. Part 1: Influence of the packaging characteristics. *Pharm Ind.* 1999;61(1):92–6.
87. van Santvliet L, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles. Part 2. *Pharm Ind.* 1999;61(2):194–8.
88. van Santvliet L, Ludwig A. Determinants of eye drop size. *Surv Ophthalmol.* 2004;49(2):197–200.
89. Šklubalová Z, Zatloukal Z. Study of eye drops dispensing and dose variability by using plastic dropper tips. *Drug Dev Ind Pharm.* 2006;32(2):197–205.
90. Yoshikawa K, Yamada H. Influence of container structures and content solutions on dispensing time of ophthalmic solutions. *Clin Ophthalmol.* 2010;4:481–6.
91. van Santvliet L, Ludwig A. Influence of the dropper tip design on the size of eye-drops. *Pharm Ind.* 2001;63(4):402–9.

92. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterisation and research methods. *ScientificWorldJournal*. 2014.
93. Rupenthal ID, Alany RG. Ocular drug delivery. In: Gad SC, Editor. *Pharmaceutical manufacturing handbook. Production and processes*. Hoboken: Wiley-InterScience; 2008.
94. Šklubalová Z. In situ gelující polymery pro oční kapky. *Čes Slov Farm*. 2005;54(1):4–10.
95. Masteiková R, Chalupová Z, Šklubalová Z. Stimuli-sensitive hydrogels in controlled and sustained drug delivery. *Medicina (Lithuania)*. 2003;39(2):19–24.
96. Jani R, Rhone E. Ion exchange resin technology for ophthalmic applications. In: Rathborne MJ, Hadgraft J, Roberts MS, Lane ME, editors. *Modified-Release Drug Delivery Technology*. 2nd Ed. Vol. 2, New York: Informa Healthcare; 2008.
97. Yarangumeli A, Kural G. Are there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other beta-blockers in the treatment of glaucoma? *Expert Opin Pharmacother*. 2004;5(5):1071–81.
98. Český lékopis 2017. Praha: Grada Publishing; 2017.
99. Burgalassi S, Chetoni P, Saettone MF. Hydrogels for ocular delivery of pilocarpine: Preliminary evaluation in rabbits of the influence of viscosity and of drug solubility. *Eur J Pharm Biopharm*. 1996;42(6):385–92.
100. Saettone MF, Salminen L. Ocular inserts for topical delivery. *Adv Drug Del Rev*. 1995;16:95–106.
101. Friedrich SW, Saville BA, Cheng YL. Pharmacokinetic differences between ocular inserts and eyedrops. *J Ocul Pharmacol Ther*. 1996;12(1):5–18.
102. Masteiková R, Chalupová Z, Savickas A. Biologická dostupnost očních léků. 2. Oční terapeutické systémy. *Čes Slov Farmacie*. 2004;53(5):211–8.
103. Gajdziok J, Vetchý D. Mukoadhezivní polymery v lékových formách. *Chem Listy*. 2012;106:632–8.
104. Khar RK, Vyas SP. Targeted and controlled drug delivery novel carrier systems. New Delhi: C.B.S. Publishers and Distributors, Inc; 2002.
105. Wilson CG, Badawi M, Hillery AM, Borooah S, Megaw R, Dhillon B. Ophthalmic drug delivery. In: Hillery AM, Park K. editors. *Drug Delivery: Fundamentals and Applications*, 2nd Ed. Boca Raton: CRC Press; 2017.
106. Lacrisert. Dostupné ke dni 29.04.2018 z: www.bausch.com/our-products/rx-pharmaceutical/lacrisert-hydroxypropyl-cellulose-ophthalmic-insert.
107. Willoughby CE, Batterbury M, Kaye SB. Collagen Corneal Shields. *Surv Ophthalmol*. 2002;47(2):174–82.
108. Liu Y, Ren L, Yao H, Wang Y. Collagen films with suitable physical properties and biocompatibility for corneal tissue engineering prepared by ion leaching technique. *Materials Letters*. 2012;87:1–4.
109. Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED, Jacob-Labarre JT, et al. Collagen-based drug delivery and artificial tears. *J Ocul Pharmacol*. 1994;10(1):17–27.
110. Baeyens V, Kaltsatos V, Boisrame B, Fathi M, Gurny R. Evaluation of soluble Bioadhesive Ophthalmic Drug Inserts (BODI) for prolonged release of gentamicin: lachrymal pharmacokinetics and ocular tolerance. *Ocul Pharmacol Ther*. 1998;14(3):263–72.
111. Furrer P, Felt O, Gurny R. Bioadhesive ophthalmic drug inserts (BODI) for veterinary use. In: Rathborne MJ, Hadgraft J, Roberts MS, Lane ME, editors. *Modified-Release Drug Delivery Technology*. 2nd Ed. Vol. 2, New York: Informa Healthcare; 2008.
112. Xinming L, Yingde C, Lloyd AW, Mikhalovsky SV, Sandeman SR, Howel CA, et al. Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review. *Cont Lens Anterior Eye*. 2008;31(2):57–64.
113. Alvarez-Lorenzo C, Yanez F, Barreiro-Iglesias R, Concheiro A. Imprinted soft contact lenses as norfloxacin delivery systems. *J Control Rel*. 2006;113(3):236–44.
114. Tieppo A, White CJ, Paine AC, Voyles ML, McBride MK, Byrne ME. Sustained in vivo release from imprinted therapeutic contact lenses. *J Control Rel*. 2012;157(3):391–7.

115. Alvarez-Lorenzo C, Hiratani H, Gómez-Amoza JL, Martínez-Pacheco R, Souto C, Concheiro A. Soft contact lenses capable of sustained delivery of timolol. *J Pharm Sci.* 2002;91(10):2182–92.
116. Hiratani H, Alvarez-Lorenzo C. Timolol uptake and release by imprinted soft contact lenses made of N,N-diethylacrylamide and methacrylic acid. *J Control Rel.* 2002;83(2):223–30.
117. Ali Y, Lehmusaaari K. Industrial perspective in ocular drug delivery. *Adv Drug Del Rev.* 2006;58(11):1258–68.
118. Mahato RI, Narang AS. *Pharmaceutical Dosage Forms and Drug Delivery.* Boca Raton: CRC Press; 2007.
119. Hitchings RA, Smith RJ. Experience with pilocarpine Ocuserts. *Trans Ophthalmol Soc UK.* 1977;97(1):202–5.
120. Chen H. Recent developments in ocular drug delivery. *J Drug Target.* 2015;23(7-8):597–604.
121. Moosa RM, Choonara YE, du Toit LC, Kumar P, Carmichael T, Tomar LK, et al. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye. *J Pharm Pharmacol.* 2014;66(4):490–506.
122. Weyenberg W, Bozdag S, Foreman P, Remon JP, Ludwig A. Characterization and in vivo evaluation of ocular minitables prepared with different bioadhesive Carbopol-starch components. *Eur J Pharm Biopharm.* 2006;62(2):202–9.
123. Bozdag S, Weyenberg W, Adriaens E, Dhondt MM, Vergote V, Vervaeet C, et al. In vitro evaluation of gentamicin- and vancomycin-containing minitables as a replacement for fortified eye drops. *Drug Dev Ind Pharm.* 2010;36(11):1259–70.
124. Masteiková R. Aplikační systémy pro léčení onemocnění vnitřního oka. *Prakt Lékáren.* 2005;1(2):100–2.
125. Christie JG, Kompella UB. Ophthalmic light sensitive nanocarrier systems. *Drug Discov Today.* 2008;13(3/4):124–34.
126. AISPL-2018.2. Dostupné ke dni 01.04.2018. Souhrn SPC Macugen 0,3MG INJ SOL.
127. AISPL-2018.2. Dostupné ke dni 01.04.2018. Souhrn SPC Lucentis 10MG/ML INJ SOL.
128. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. *Pharm Res.* 2010;27(10):2043–53.
129. Bossy L, Erickson S, Gurny R, Delie F. Intraocular implants for controlled drug delivery. In: Rathborne MJ, Hadgraft J, Roberts MS, Lane ME, editors. *Modified-Release Drug Delivery Technology.* 2nd Ed. Vol. 2, New York: Informa Healthcare; 2008.
130. Ozurdex. Dostupné ke dni 30.04.2018 z: www.ozurdex.com.
131. Tan DT, Chee SP, Lim L, Theng J, vanEde M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. *Ophthalmology.* 2001;108(12):2172–81.
132. Iluvien. Dostupné ke dni 02.05. 2018 z: www.alimerasciences.com/products/iluvien-for-diabetic-macular-edema-dme.
133. Jervis LP. A Summary of Recent Advances in Ocular Inserts and Implants. *Journal of Bioequivalence & Bioavailability.* 2017;9(1):320–3.
134. Wong FSY, Tsang KK, Lo ACY. Delivery of therapeutics to posterior eye segment: cell-encapsulating systems. *Neural Regen Res.* 2017;12(4):576–77.
135. Zimčík P, Miletín M. Fotodynamická terapie jako nová perspektivní metoda léčby nádorových onemocnění I. Historie, základní princip. *Čes Slov Farm.* 2004;53(5):219–24.
136. Zimčík P, Miletín M. Fotodynamická terapie jako nová perspektivní metoda léčby nádorových onemocnění II. Přehled fotosenzitizérů. *Čes Slov Farm.* 2004;53(6):271–9.
137. Obaid G, Broekgaarden M, Bulin AL, Huang HC, Kuriakose J, Liu J, et al. Photomedicine: a convergence of photodynamic therapy and nanotechnology. *Nanoscale.* 2016;8(25):12471–503.
138. AISPL-2018.2. Dostupné ke dni 01.04.2018. Souhrn SPC Visudyne 15 mg inf plv sol.

139. Medi-Dose. Sterile dropping bottles. Dostupné ke dni 25.04.2018 z: www.medidose.com/Steri-Dropper-Bottles.aspx.
140. Evans D, Kuo T, Kwong M, Van R, Fleiszig S. Pseudomonas aeruginosa strains with lipopolysaccharide defects exhibit reduced intracellular viability after invasion of corneal epithelial cells. *Exp Eye Res.* 2002;75(6):635–43.
141. Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. *Prog Ret Eye Res.* 2004;23(1):1–30.
142. Armstrong RA. The microbiology of the eye. *Ophth Phys Opt.* 2000;20(6):429–41.
143. Cabrera JV, Rodriguez JB. Ocular bacterial flora in contact lens wearers. *Int Cont Lens Clin.* 1996;23(4):149–51.
144. Agalloco J, Akers J. Sterile product manufacturing. In: Gad SC, editor: *Pharmaceutical manufacturing handbook. Production and processes.* Hoboken: Wiley-InterScience; 2008.
145. Schein OD, Hibberd PL, Starck T, Baker AS, Kenyon KR. Microbial-contamination of in-use ocular medications. *Arch Ophthalmol.* 1992;110(1):82–5.
146. Coad CT, Osato MS, Wilhelmus KR. Bacterial-contamination of eyedrop dispensers. *Am J Ophthalmol.* 1984;98(5):548–51.
147. Geyer O, Bottone EJ, Podos SM, Schumer RA, Asbell PA. Microbial-contamination of medications used to treat glaucoma. *Br J Ophthalmol.* 1995;79(4):376–9.
148. Ingham A, Poon YC. Tonicity, Osmoticity, Osmolality and Osmolarity. In: Allen LV, editor. *Remington: The science and practice of pharmacy.* 22nd Ed. London, Philadelphia: Pharmaceutical Press; 2013.
149. Ali Y, Lehmuusaari K. Industrial perspective in ocular drug delivery. *Adv Drug Del Rev.* 2006;58(11):1258–68.
150. Thompson JE, editor. *A practical guide to Contemporary Pharmacy Practice.* 3rd Ed. Baltimore, Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2009.
151. Richards RME. Ophthalmic products. In: Winfield AJ, Rees JA, Smith I, editors. *Pharmaceutical practice.* Edinburgh: Churchill Livingstone; 2009.
152. Pilatti C, Torre MC, Chiale C, Spinetto M. Stability of pilocarpine ophthalmic solutions. *Drug Dev Ind Pharm.* 1999;25(6):801–5.
153. Kolko M, Jensen PK. The physical properties of generic latanoprost ophthalmic solutions are not identical. *Acta Ophthalmol.* 2017;95(4):370–3.
154. Pescina S, Carra F, Padula C, Santi P, Nicoli S. Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transport. *Eur J Pharm Biopharm.* 2016;107:171–9.
155. Allen LV, Popovich NG, Ansel HC. *Pharmaceutical dosage forms and drug delivery systems.* 8th Ed., Baltimore: Lippincott Williams & Wilkins; 2005.
156. Schuerer N, Stein E, Inic-Kanada A, Pucher M, Hohenadl C, Bintner N, et al. Implications for ophthalmic formulations: Ocular buffers show varied cytotoxic impact on human corneal-limbal and human conjunctival epithelial cells. *Cornea.* 2017;36(6):712–8.
157. Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. *Toxicol Lett.* 2001;122:1–8.
158. Kulkarni SP, Bhanumathi B, Thoppil SO, Bhogte CP, Vartak D, Amin PD. Dry eye syndrome. *Drug Dev Ind Pharm.* 1997;23(5):465–471.
159. Mastropietro DJ, Omidian H. Prevalence and trends of cellulose in pharmaceutical dosage forms. *Drug Dev Ind Pharm.* 2013;39(2):382–92.
160. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. *Adv Drug Del Rev.* 2002;54(1):37–51.
161. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: a novel, ion-activated in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. *Int J Pharm.* 1989;57(2):163–8.
162. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic delivery system from alginates undergoing gelation in the eye. *J Control Rel.* 1997;44:201–8.

163. Tønnesen HH, Karlsen J. Alginate in drug delivery systems. *Drug Dev Ind Pharm.* 2002;28(6):621–30.
164. Carlfors J, Edsman K, Petersson R, Jörnving K. Rheological evaluation of Gelrite® in situ gels for ophthalmic use. *Eur J Pharm Sci.* 1998;6(2):113–9.
165. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. *J Control Rel.* 2000;69(3):379–88.
166. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. *Int J Pharm.* 2002;241(1):47–55.
167. Escobar-Chávez JJ, López-Cervantes M, Naik A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. *J Pharm Pharm Sci.* 2006;9(3):339–58.
168. Matschke C, Isele U, van Hoogevest P, Fahr A. Sustained-release injectables formed in situ and their potential use for veterinary products. *J Control Rel.* 2002;85(1–3):1–15.
169. Cohn D, Sosnik A, Levy A. Improved reverse thermo-responsive polymeric systems. *Biomaterials*2003;24(21):3707–14.
170. Ohno Y, Iga T, Yamada Y, Nagahara M, Araie M, Takayanagi R. Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). *Curr Eye Res.* 2005;30:319–28.
171. www.insitevision.com/product_pipeline.html. Dostupné ke dni 26.01.2018.
172. Barreiro-Iglesias R, Alvarez-Lorenzo C, Concheiro A. Poly(acrylic acid) microgels (carbopol® 934)/surfactant interactions in aqueous media: Part I: Nonionic surfactants. *Int J Pharm.* 2003;258(1–2):165–77.
173. Barreiro-Iglesias R, Alvarez-Lorenzo C, Concheiro A. Poly(acrylic acid) microgels (carbopol® 934)/surfactant interactions in aqueous media: Part II: Ionic surfactants. *Int J Pharm.* 2003;258(1–2):179–91.
174. Alonso MJ, Sánchez A. The potential of chitosan in ocular drug delivery. *J Pharm Pharmacol.* 2003;55(11):1451–63.
175. Scoper SV, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, et al. Ocular distribution, bactericidal activity and settling characteristics of Tobradex ST ophthalmic suspension compared with Tobradex ophthalmic suspension. *Adv Ther* 2008;25(2):77–88.
176. Jansson PE, Lindberg B, Stanford PA. Structural studies of gellan gum, an extracellular polysaccharide elaborated by *Pseudomonas elodea*. *Carbohydr Res.* 1983;124:135–9.
177. Giavasis I, Harvey LM, McNeil B. Gellan gum. *Crit Rev Biotechnol.* 2000;20(3):177–211.
178. Tang J, Mao R, Tung MA, Swanson BG. Gelling temperature, gel clarity and texture of gellan gels containing fructose or sucrose. *Carbohydr Polym.* 2001;44(3):197–209.
179. Sutherland IW. Microbial polysaccharides from Gram-negative bacteria. *Int Dairy J.* 2001;11(9):663–74.
180. Lang JC, Roehrs RE, Jani R. Ophthalmic preparations. In: Troy DB, editor. Remington: The science and practice of pharmacy. 21thEd., Philadelphia: Lippincott Williams & Wilkins; 2005.
181. Eriksen SP. Preservation of ophthalmic, nasal and otic products. *Drug Cosmet Ind.* 1970;107:36–40.
182. Denyer SP, Baird RM. Guide to microbiological control in pharmaceuticals and medical devices. 2nd ed. Boca Raton, Fla.: CRC Press; 2006.
183. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. *Eur J Pharm Biopharm.* 2002;53(3):263–80.
184. Šklubalová Z. Protimikrobní látky v očních kapkách. *Čes Slov Farm.* 2004;53(3):107–16.
185. Tressler CS, Beatty R, Lemp MA. Preservative use in topical glaucoma medications. *Ocul Surf.* 2011;9(3):140–58.

186. Rolando M, Crider JY, Kahook MY. Ophthalmic preservatives: focus on polyquaternium-1. *Expert Opin Drug Deliv.* 2011;8(11):1425–38.
187. Ammar DA, Noecker RJ a kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. *Adv Ther.* 2011;28(6):501–10.
188. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. *Adv Ther.* 2010;27(11):837–45.
189. Noecker R. Effects of common ophthalmic preservatives on ocular health. *Adv Ther.* 2001;18(5):205–15.
190. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. *J Ocul Pharmacol Ther.* 2009;25(2):113–9.
191. Efficacy of antimicrobial preservation. 5.1.3. *European Pharmacopoeia 9.0*; 2017.
192. Disinfectants and antiseptics. 1072 USP 40; 2017.
193. Moser CL, Meyer BK. Comparison of compendial antimicrobial effectiveness tests: A review. *AAPS PharmSciTech.* 2011;12(1):222–6.
194. Ryan G, Fain JM, Lovelace C, Gelotte KM. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system. *BMC Ophthalmology.* 2011;11:8.
195. Freeman DP, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. *Expert Review of Ophthalmology.* 2009;4:59–64.
196. Rowe RC, Sheskey PJ, Cook QG, Cable CG. *Handbook of Pharmaceutical Excipients.* 8th ed. London: Pharmaceutical Press; 2017.
197. Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. *Mol Vis.* 2011;17:1806–13.
198. Epstein SP, Chen D, Asbell PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. *J Ocul Pharmacol Ther.* 2009;25(5):415–24.
199. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. *Cutan Ocul Toxicol.* 2009;28(3):93–103.
200. Zeng P, Rao A, Wiedmann TS, Bowles W. Properties of chlorhexidine salts. *Drug Dev Ind Pharm.* 2009;35:172–6.
201. AISPL-2018.2. Dostupné ke dni 01.04.2018. Souhrn SPC Ophthalmoseptonex.
202. Higashiyama M, Inada K, Ohtori A, Tojo K. Improvement of the ocular bioavailability of timolol by sorbic acid. *Int J Pharm.* 2004;272(1–2):91–8.
203. Tu EY. Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. *Saudi J Ophthalmol.* 2014;28(3):182–7.
204. Paimela T, Ryhänen T, Kauppinen A, Marttila L, Salminen A, Kaarniranta K. The preservative polyquaternium-1 increases cytotoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. *Mol Vis.* 2012;18:1189–96.
205. Labbé A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet JM, et al. Comparison of Toxicological Profiles of Benzalkonium Chloride and Polyquaternium-1: An Experimental Study. *J Ocul Pharmacol Ther.* 2006;22:267–78.
206. Banker GS, Rhodes CT, editors. *Modern Pharmaceuticals, 1.* 5th ed. Hoboken: Informa Healthcare; 2002.
207. Tu EY. Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. *Saudi J Ophthalmol.* 2014;28:182–7.
208. Ali Y, Lehmuskaari K. Industrial perspective in ocular drug delivery. *Adv Drug Del Rev.* 2006;58(11):1258–68.
209. *Československý lékopis. 4. vyd. Tabulka VIII. Roztoky izoacidní a euacidní.* Praha: Avicenum; 1987.

210. Deutscher arzneimittel-codex, neues rezeptur-formularium-rezepturhinweise: Epinephrin zur Anwendung im Auge: Eschborn; 2006.
211. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery *Adv Drug Deliv Rev.* 2008;60(15):1663–73.
212. Pogorzelski S, Watrobska-Swietlikowska D, Sznitowska M. Surface tensometry studies on formulations of surfactants with preservatives as a tool for antimicrobial drug protection characterisation. *J Biophysical Chem.* 2012;3(4):324–33.
213. Sznitowska M, Janicki S, Dabrowska EA, Gajewska M. Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. *Eur J Pharm Sci.* 2002;15(5):489–95.
214. Alexandridis P, Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling. *Colloids and Surfaces A: Physicochemical and Engineering Aspects.* 1995;96:1–46.
215. Tarcha PJ. *Polymers for controlled drug delivery.* Boca Raton: CRC Press; 1990.
216. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of Poloxamer 407 pharmaceutical and pharmacological characteristics. *Pharm Res.* 2006;23(12):2709–28.
217. Daher CF, Baroody GM, Howland RJ. Effect of a surfactant, Tween 80, on the formation and secretion of chylomicrons in the rat. *Food Chem Toxicol.* 2003;41(4):575–82.
218. Tatsuishi T, Oyama Y, Iwase K, Yamaguchi JY, Kobayashi M, Nishimura Y, et al. Polysorbate 80 increases the susceptibility to oxidative stress in rat thymocytes. *Toxicology.* 2005;207(1):7–14.
219. Wang W, Wang YJ, Wang DQ. Dual effect of Tween 80 on protein stability. *Int J Pharm.* 2008;347:31–8.
220. Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppänen A, Kaja S, Kalesnykas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. *Int J Pharm.* 2016;511(1):73–8.
221. Polifka JE, Habermann J. Anticoagulants, thrombocyte aggregation inhibitors, fibrinolytics and volume replacement agents. *Drugs During Pregnancy and Lactation.* 3rd. Philadelphia: Elsevier; 2015.
222. Svensén C, Rodhe P. *Pharmacology and physiology for anesthesia.* Philadelphia: Elsevier Saunders; 2013.
223. Warden GD. *Total burn care.* 3rd. Edinburgh: Saunders Elsevier; 2007.
224. Kogan G, Šoltés L, Stern R, Gemeiner P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. *Biotechnol Lett.* 2007;29(1):17–25.
225. Pechová V, Gajdziok J. Možnosti využití hyaluronátu sodného ve farmacii a medicíně. *Čes Slov Farm.* 2017;66:154–9.
226. Sosnik A, Das Neves J, Sarmiento B. Mucoadhesive polymers in the design of nanodrug delivery systems for administration by non-parenteral routes: A review. *Prog Polym Sci.* 2014;39:2030–75.
227. Šedová P, Buffa R, Kettou S, Huerta-Angeles G, Hermannová M, Leierová V, et al. Preparation of hyaluronan polyaldehyde-a precursor of biopolymer conjugates. *Carbohydr Res.* 2013;371:8–15.
228. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. *J Intern Med.* 1997;242(1):27–33.
229. Schiller J, Volpi N, Hrabárová E, Šoltés L. Hyaluronic acid: A natural biopolymer. In: Kalia S, Avérous L, editors. *Biopolymers: Biomedical and environmental applications.* Hoboken: John Wiley and Sons; 2011.
230. Uhart M, Pirot F, Boillon A, Senaux E, Tall L, Diouf E, et al. Assessment of sodium hyaluronate gel as vehicle for intracameral delivery of cefuroxime in endophthalmitis prophylaxis. *Int J Pharm.* 2010;398(1–2):14–20.

231. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. *Vet Med.* 2008;53:397–411.
232. Nepp J, Schauersberger J, Schild G, Jandrasits K, Haslinger-Akramian J, Derbolav A, et al. The clinical use of viscoelastic artificial tears and sodium chloride in dry-eye syndrome. *Biomaterials.* 2001;22(24):3305–10.
233. Calogne M. The Treatment of Dry Eye. *Survey of Ophthalmology.* 2001;45(2):227–39.
234. Uhart M, Pirot F, Boillon A, Senaux E, Tall L, Diouf E, et al. Assessment of sodium hyaluronate gel as vehicle for intracameral delivery of cefuroxime in endophthalmitis prophylaxis. *Int J Pharm.* 2010;398(1–2):14–20.
235. Cholkar K, Acharya G, Trinh HM, Singh G. Therapeutic Applications of Polymeric Materials. In: Mitra A, Cholkar K, Mandal A, editors. *Emerging nanotechnologies for diagnostics, drug delivery and medical devices.* Amsterdam: Elsevier; 2017.
236. Lowry KM, Beavers EM, Trinh HM, Singh G. Thermal stability of sodium hyaluronate in aqueous solution. *Journal of Biomedical Materials Research.* 1994;28:1239–44.
237. Caspersen MB, Roubroeks JP, Qun L, Shan H, Fogh J, Ruidong Z, et al. Thermal degradation and stability of sodium hyaluronate in solid state. *Carbohydr Polym.* 2014;107:25–30.
238. Bajerová M, Gajdziok J, Dvořáčková K, Masteiková R, Kollar P. Polosyntetické deriváty celulosy jako základ hydrofilních gelových systémů. *Čes Slov Farm.* 2008;57(2):63–9.
239. Rabišková M, Vostálová L, Medvecká G, Horáčková D. Hydrofilní gelové matricové tablety pro perorální aplikaci léčiv. *Čes Slov Farm.* 2003;52(5):211–7.
240. Dow Chemical Company. *Methocel Cellulose Ethers Technical Handbook.* USA; 2002.
241. Ghimire M, Hodges LA, Band J, O'Mahony B, McInnes FJ, Mullen AB, et al. In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets. *J Control Release.* 2010;147(1):70–5.
242. Vostálová L, Rabišková M, Medvecká G. Uvolňování diltiazemiumchloridu a ibuprofenu z hydrofilních matricových tablet. *Čes Slov Farm.* 2003;52(6):295–8.
243. Dvořáčková K. Principy uvolňování léčiv z perorálních matricových tablet obsahujících hypromelosu. *Chem Listy.* 2009;103(1):66–72.
244. Zatloukal Z. Ovlivnění pseudoplastického hydrogelu přísadou pilokarpinium chloridu. *Čes Slov Farm.* 2003;52(3):131–5.
245. Zatloukal Z, Šklubalová Z. Sterilized ophthalmic hydrogels with hydroxypropyl methylcellulose: determination and mathematical treatment of flow properties. *Pharm Dev Technol.* 2007;12(1):55–60.
246. Krówczynski L, Rybacki E. *Interakcie vo farmaceutickej fáze.* Martin: Osveta; 1989.
247. Brady J, Dürig T, Lee PI, Li JX. *Polymer Properties and Characterization.* In: Qiu Y, Chen Y, Yu GZL, Mantri RV, editors. *Developing solid oral dosage forms.* 2nd. Boston: Elsevier Academic Press; 2017.
248. Kariduraganavar MY, Kittur AA, Kamble RR. *Polymer Synthesis and Processing.* In: Kumbar S, Laurencin C, Deng M, editors. *Natural and synthetic biomedical polymers.* Burlington: Elsevier; 2014.
249. AISPL-2018.2. Dostupné ke dni 02.05.2018. Souhrn SPC Braunol drm. sol.
250. Farrar D, editor. *Advanced wound repair therapies.* Oxford: Woodhead Pub; 2011.
251. Wu L, Brazel CS. Modifying the release of proxiphylline from PVA hydrogels using surface crosslinking. *Int J Pharm.* 2008;349(1–2):144–51.
252. Doble M, Kumar A, editors. *Biotreatment of Industrial Effluents.* 1st. New York: Elsevier; 2005.
253. Jain D, Kumar V, Singh S, Mullertz A, Bar-Shalom D. Newer trends in in situ gelling systems for controlled ocular drug delivery. *J Anal Pharmacol Res.* 2016;2(3):1–16.
254. Mesbah NM, Wiegel J. Isolation, cultivation and characterization of alkalithermophiles. *Methods in Microbiology.* 2006;35:451–68.
255. Giavasis I, Harvey LM, McNeil B. Gellan gum. *Crit Rev Biotechnol.* 2000;20(3):177–211.

256. Sanzgiri YD, Maschi S, Crescenzi V, Callegaro L, Topp EM, Stella VJ. Gellan-based systems for ophthalmic sustained delivery of methylprednisolone. *J Control Rel.* 1993;26(3):195–201.
257. Gunning FP, Greve EL, Bron AM, Bose JM, Royer JG, George JL, et al. Two typical carboanhydrase inhibitors sezolamide and drozolamide in gelrite vehicle: a multiple-dose efficacy study. *Graefe's Arch Clin Exp Ophthalmol.* 1993;231:384–8.
258. Rozier A, Mazuel C, Grove J, Plazonnet B. Functionality testing of gellan gum, a polymeric excipient material for ophthalmic dosage forms. *Int J Pharm.* 1997;153(2):191–8.
259. Paulsson M, Hägerström H, Edsman K. Rheological studies of the gelation of deacetylated gellan gum (Gelrite) in physiological conditions. *Eur J Pharm Sci.* 1999;9(1):99–105.
260. Shedden A, Laurence J, Tipping R. Timoptic-XE 0.5% Study Group: Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. *Clinical Therapeutics.* 2001;23(3):440–50.
261. Krauland AH, Leitner VM, Bernkop-Schnürch A. Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of thiol groups. *J Pharm Sci.* 2003;92(6):1234–41.
262. Khor E, Lim LY. Implantable applications of chitin and chitosan. *Biomaterials.* 2003;24(13):2339–49.
263. Chenite A, Chaput C, Wang D, Combes C, Bushmann MD, Hoemann CH, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ for bioactive therapeutic delivery. *Biomaterials.* 2000;21(21):2155–61.
264. San JA, Montembault A, Gillet D, Say JP, Rouif S, Bouet T, et al. Degradation of chitosan-based materials after different sterilization treatments. In: *OP Conference Series: Materials Science and Engineering* 31. 2012.
265. Galante R, Redigueri CF, Kikuchi IS, Vasquez PAS, Colaço R, Serro AP, et al. About the Sterilization of Chitosan Hydrogel Nanoparticles. *PLoS One.* 2016;11:1–18.
266. Bernkop-Schnürch A, Hornof M, Guggi D. Thiolated chitosans. *Eur J Pharm Biopharm.* 2004;57(1):9–17.
267. Ünlü N, Ludwig A, van Ooteghem M, Hincal AA. A comparative rheological study on Carbopol viscous solutions and, the evaluation of their suitability as the ophthalmic vehicles and artificial tears. *Pharm Acta Helv.* 1992;6(1):5–10.
268. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. *J Control Rel.* 2001;73(2–3):205–11.
269. Kumar S, Haglund BO, Himmelstein KJ. In situ forming gels for ophthalmic drug delivery. *J Ocular Pharmacol.* 1994;10(1):47–56.
270. Oechsner M, Keipert S. Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome. *Eur J Pharm Biopharm.* 1999;47(2):113–8.
271. Sedláková M, Rabišková M, Spilková J. Přírodní polymery pro formulaci hydrofilních matricových tablet. *Čes Slov Farm.* 2006;55(1):4–11.
272. Lucinda-Silva RM, Salgado HRN, Evangelista RC. Alginate–chitosan systems: In vitro controlled release of triamcinolone and in vivo gastrointestinal transit. *Carbohydrate Polymers.* 2010;81:2260–8.
273. Sriamornsak P, Nunthanid J, Luangtana-Anan M, Weerapol Y, Puttipatkhachorn S. Alginate-based pellets prepared by extrusion/spheronization: Effect of the amount and type of sodium alginate and calcium salts. *Eur J Pharm Biopharm.* 2008;69(1):274–84.
274. Ching AL, Liew CV, Heng PW, Chan LW. Impact of cross-linker on alginate matrix integrity and drug release. *Int J Pharm.* 2008;355(1-2):259–68.
275. Liu X, Qian L, Shu T, Tong Z.: Rheology characterization of sol–gel transition in aqueous alginate solutions induced by calcium cations through in situ release. *Polymer.* 2003;44(2):407–12.

276. Chan LW, Heng PWS.: Effects of poly(vinylpyrrolidone) and ethylcellulose on alginate microspheres prepared by emulsification. *J Microencaps.* 1998;15(4):409–20.
277. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. *J Control Rel.* 2002;80(1–3):9–28.
278. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. *Eur J Pharm Sci.* 1998;6(2):105–12.
279. Mortensen K, Pedersen S. Structural study on micelle formation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer in aqueous solution. *Macromolecules.* 1993;26:805–12.
280. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. *J Control Rel.* 2002;83(1):65–74.
281. Hoffman AS. Intelligent polymers in medicine and biotechnology. *Artif Organs.* 1995;19(5):458–67.
282. Chen G, Hoffman AS. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. *Nature.* 1995;373(6509):49–52.
283. Orkisz MJ, Bromberg L, Pike R, Lupton EC, Ron ES. Rheological properties of reverse thermogelling poly(acrylic acid)-g-poly(oxyethylene-b-oxypropylene-b-oxyethylene) polymers (Smart Hydrogel™). *Proc Polym Mater Sci Eng.* 1997;76:276–7.
284. Bromberg LE, Ron ES. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. *Adv Drug Del Rev.* 1998;31(3):197–221.
285. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. *Int J Pharm.* 2002;241(1):47–55.
286. Poon K, Castellino V, Cheng Y-L. Polymeric hydrophilic polymers in targeted drug delivery. In: Prakash S. Artificial cells, cell engineering and therapy. Woodhead Publishing; 2014.
287. Zhu Z, Zhai Y, Zhang N, Leng D, Ding P. The development of polycarbophil as a bioadhesive material in pharmacy. *Asian J Pharm Sci.* 2013;8:218–27.
288. Krenzer KL, Zhang J-Z, Coffey MJ, Richardson ME. Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits. *J Cataract Refract Surg.* 2012;38(4):696–704.
289. Okano T, Bae YH, Jacobs H, Kim SW. Thermally on-off switching polymers for drug permeation and release. *J Control Rel.* 1990;11(1–3):255–65.
290. Hirokawa Y, Jinnai H, Nishikawa Y, Okamoto T, Hashimoto T. Direct observation of internal structures in poly(N-isopropylacrylamide) chemical gels. *Macromolecules.* 1999;32(21):7093–9.
291. Kaufman PL, Lütjen-Drecoll E, Hubbard WC, Erikson KA. Obstruction of aqueous humor outflow by cross-linked polyacrylamide microgels in bovine, monkey and human eyes. *Ophthalmology.* 1994;101(10):1672–9.